slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 73,261-73,290
Pages 3,679
Rows per page 30
Component
73,261-73,290 of 110,355
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
16
Includes FDA approval precedents in the footer to establish credibility.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
19
The slide uses a side-by-side comparison structure to explain two distinct but complementary technology platforms.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
21
Combines market sizing data with a 'Why Now' narrative supported by industry news clippings and a comparative efficacy table.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit
22
The slide uses a wave-like visual to represent market segments and their associated valuations.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit
25
The chart uses a grouped bar structure to compare efficacy across patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
26
The slide uses a comparison table framework to highlight competitive advantage in clinical metrics.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
27
The slide uses a two-column layout to compare clinical data for two different indications, supported by competitor market data.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
29
The table displays clinical trial data for NXC-201, specifically focusing on Cytokine Release Syndrome (CRS) and Immune cell associated Neurotoxicity (ICANS).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
32
The diagram illustrates a classic dose-escalation study design.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
35
Includes scientific diagrams of molecular pathways and efficacy charts.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
41
The slide uses a scatter plot to map clinical trial outcomes (mPFS vs. prior lines of therapy) and a table to detail standard-of-care performance across lines of therapy.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
42
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a late-stage patient population.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
45
The slide uses a process-flow style layout to connect platform capabilities to specific therapeutic assets.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
47
Includes technical diagrams of the drug molecule, comparative histology, and survival curves.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
48
Includes two sets of charts: tumor volume line graphs and survival curves. References specific dosing schedules and study parameters.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
49
The slide uses a combination of mechanism-of-action diagrams and clinical/preclinical data charts to validate the therapeutic approach.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
56
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
57
The slide uses a bar chart to compare two groups of oncology drugs, highlighting a significant revenue disparity.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Action1 hit
04
The slide uses a grid layout to present six distinct performance categories.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Humble Origins1 hit
07
The slide uses a mix of brand logos and a bar chart to illustrate portfolio composition and financial scale.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early Struggles1 hit
08
Uses a before-after framework to illustrate strategic evolution.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
16
The slide highlights investment activities and financial health indicators.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Rising Success1 hit
36
The matrix uses a 3x3 grid structure to categorize priorities. Icons represent People, Planet, Governance, and Profit.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
37
The slide lists various sustainability initiatives (SBTi, Fashion Pact, RE100, CDP, TCFD) alongside specific quantitative reduction targets.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
40
Includes a visual comparison of land footprint vs. restoration target.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
42
The diagram is a circular process model showing how different operational areas contribute to circularity.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
43
The slide uses donut charts and a map to visualize workforce composition across multiple dimensions.Kering | Investor Presentation Deck | 55 slides · Kering
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
09
Includes a footnote regarding the acquisition closing date.Lakeland Bancorp | Results Presentation Deck | 14 slides · Lakeland
Conference presentation Investor relations Loop · Cost Of Inaction1 hit